Researchers at ETH Zurich combined two CRISPR-Cas methods to decipher how mutations in a cell’s genome affect its function.

University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...

Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target ...

In recent years, scientists have created a range of new methods based on CRISPR-Cas technology for precisely editing the ...

Salim Syed’s rating is based on a combination of encouraging developments surrounding Crispr Therapeutics AG. Firstly, the pricing of Casgevy in Saudi Arabia appears to be around $2 million per ...

FDA clearance of HG202 marks a significant milestone for CRISPR/Cas13 RNA-editing in clinical applications for nAMD. The ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

The patents have been officially revoked following the pair's voluntary decision to withdraw them | Withdrawal follows ...

Life Sciences Center (LSC) have discovered a unique way for cells to silence specific genes without cutting DNA. This ...

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA to proteins. But only two percent of the human genome actually encodes ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

T here are some seriously strange lifeforms lurking in the depths of our oceans – ghost sharks and upside-down isopods, ...